Johnson & Johnson (NYSE:JNJ) Holdings Raised by Capital Square LLC

Capital Square LLC boosted its stake in Johnson & Johnson (NYSE:JNJ) by 16.9% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 5,868 shares of the company’s stock after buying an additional 848 shares during the period. Capital Square LLC’s holdings in Johnson & Johnson were worth $862,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of JNJ. Principal Financial Group Inc. lifted its holdings in shares of Johnson & Johnson by 10.5% in the third quarter. Principal Financial Group Inc. now owns 3,472,312 shares of the company’s stock valued at $562,723,000 after buying an additional 329,473 shares during the period. Invst LLC raised its position in Johnson & Johnson by 394.0% in the third quarter. Invst LLC now owns 10,290 shares of the company’s stock worth $1,668,000 after acquiring an additional 8,207 shares in the last quarter. McIlrath & Eck LLC lifted its holdings in Johnson & Johnson by 10.7% in the 3rd quarter. McIlrath & Eck LLC now owns 2,892 shares of the company’s stock valued at $469,000 after acquiring an additional 279 shares during the last quarter. Passumpsic Savings Bank bought a new position in shares of Johnson & Johnson during the 3rd quarter valued at about $262,000. Finally, Te Ahumairangi Investment Management Ltd grew its stake in shares of Johnson & Johnson by 10.1% in the 3rd quarter. Te Ahumairangi Investment Management Ltd now owns 50,765 shares of the company’s stock worth $8,180,000 after purchasing an additional 4,640 shares during the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Insider Activity at Johnson & Johnson

In related news, EVP Timothy Schmid sold 403 shares of the stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total value of $62,928.45. Following the completion of the sale, the executive vice president now owns 15,098 shares in the company, valued at approximately $2,357,552.70. This trade represents a 2.60 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Robert J. Decker sold 6,999 shares of the firm’s stock in a transaction that occurred on Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total value of $1,160,994.12. Following the completion of the sale, the vice president now owns 21,001 shares of the company’s stock, valued at $3,483,645.88. This represents a 25.00 % decrease in their position. The disclosure for this sale can be found here. 0.16% of the stock is currently owned by company insiders.

Johnson & Johnson Stock Performance

Shares of JNJ opened at $153.95 on Thursday. The firm has a market cap of $371.00 billion, a price-to-earnings ratio of 23.15, a price-to-earnings-growth ratio of 2.56 and a beta of 0.49. The company’s fifty day moving average is $159.40 and its 200-day moving average is $155.10. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 0.43. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $169.99.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Tuesday, April 15th. The company reported $2.77 EPS for the quarter, topping the consensus estimate of $2.59 by $0.18. The firm had revenue of $21.89 billion for the quarter, compared to the consensus estimate of $21.65 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. Equities analysts expect that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 10th. Investors of record on Tuesday, May 27th will be issued a dividend of $1.30 per share. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.24. This represents a $5.20 annualized dividend and a dividend yield of 3.38%. The ex-dividend date of this dividend is Tuesday, May 27th. Johnson & Johnson’s dividend payout ratio is currently 74.59%.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on the stock. Guggenheim restated a “neutral” rating on shares of Johnson & Johnson in a report on Wednesday, April 2nd. Barclays raised their price objective on Johnson & Johnson from $159.00 to $166.00 and gave the stock an “equal weight” rating in a research note on Tuesday, January 28th. Argus raised Johnson & Johnson to a “strong-buy” rating in a research report on Friday, January 24th. The Goldman Sachs Group upgraded Johnson & Johnson from a “neutral” rating to a “buy” rating and increased their price target for the company from $157.00 to $172.00 in a research report on Wednesday, April 9th. Finally, Stifel Nicolaus reduced their price objective on shares of Johnson & Johnson from $170.00 to $155.00 and set a “hold” rating for the company in a research note on Thursday, January 23rd. Nine analysts have rated the stock with a hold rating, nine have issued a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $171.78.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.